Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

CH, Köhne; Cutsem E, van; J, Wils; C, Bokemeyer; M, El-Serafi; MP, Lutz; M, Lorenz; P, Reichardt; H, Rückle-Lanz; N, Frickhofen; R, Fuchs; HG, Mergenthaler; T, Langenbuch; U, Vanhoefer; P, Rougier; R, Voigtmann; L, Müller; B, Genicot; O, Anak; B, Nordlinger

doi:10.1200/jco.2005.05.546

Public

Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

Shared by NobleBlocks on Jun 6, 2005 • 12:00 AM UTC

Authors:

Köhne CH

van Cutsem E

Wils J

Abstract

Purpose To demonstrate that adding irinotecan to a standard weekly schedule of high-dose, infusional fluorouracil (FU) and leucovorin (folinic acid [FA]) can prolong progression-free survival (PFS).Patients and methods Four hundred thirty patients with measurable or assessable metastatic colorectal ...

Discussions